Photo taken from Chiaojung Jillian Tsai/LinkedIn
Dec 21, 2023, 09:57
Chiaojung Jillian Tsai: CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer
Chiaojung Jillian Tsai, Lead of Palliative Radiotherapy and Oligometastasis Program (PROP) at Princess Margaret Cancer Centre, posted on LinkedIn:
“Just out The Lancet:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 06:21
Dec 23, 2024, 06:08
Dec 23, 2024, 06:05
Dec 23, 2024, 06:00
Dec 23, 2024, 05:43
Dec 22, 2024, 18:02
Dec 22, 2024, 17:54
CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer. SBRT improved PFS by 4 times in NSCLC, but not in oligoprogressive metastatic breast cancer in the study population. Local therapy in patients with oligoprogressive cancer might alter patterns of anatomical progression. Patients with breast cancer in either groups mostly grow new lesions while patients NSCLC in the SBRT group had fewer progressions in pre-existing lesions.Analyses of paired pre- and post-randomization blood showed that SBRT led to changes in circulating tumor DNA metrics in patients with NSCLC, but not breast cancer.
Early integration of radiotherapy in multidisciplinary management of patients with metastatic cancer is crucial for optimizing patient wellbeing and outcomes.”